Abstract
ObjectivesUp to 50% of heart failure (HF) patients may be frail and have worse clinical outcomes than non-frail patients. The benefits of HF-specific pharmacotherapy (beta-blockers, ACE-inhibitors/angiotensin-receptor-blockers and mineralocorticoid-receptor-antagonist) in this...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have